The FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to United Therapeutics' investigational miroliverELAP for acute liver failure. The RMAT status can accelerate regulatory interactions and review, de-risking development timelines and potentially supporting upside for the company's program, though it is not an approval and clinical/commercial risks remain.
The FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to United Therapeutics' investigational miroliverELAP for acute liver failure. The RMAT status can accelerate regulatory interactions and review, de-risking development timelines and potentially supporting upside for the company's program, though it is not an approval and clinical/commercial risks remain.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
